---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-009994"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T05:10:07.908773+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42

## Summary
- GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.
- Protein Sciences segment revenue +2% to $215.1M; operating margin fell to 39.3% from 41.2%.
- Diagnostics & Spatial Biology segment revenue -4% to $81.2M; organic growth +3% with margin up to 10.4%.
- Board declares $0.08/share quarterly dividend, payable Feb 27, 2026 to holders of record Feb 16, 2026.
- China/APAC region drove growth for third consecutive quarter; large pharma end-market grew double digits.

## SEC filing metadata
- accession: 0001104659-26-009994
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000110465926009994/0001104659-26-009994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000110465926009994/tech-20260204x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-009994
- JSON: https://secwatch.observer/filing/0001104659-26-009994.json
- Plain text: https://secwatch.observer/filing/0001104659-26-009994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.